The Ebbs and Flows in the Development of Cholesterol‐Lowering Drugs: Prospects for the Future

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Clinical pharmacology and therapy

• Publication date

  2014-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/clpt.2014.76PMID 24699033
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol–Lowering Therapy for the Treatment of Patients With Hypercholesterolemia and Type 2 Diabetes Mellitus

  2014cited by this paper
• A Statin-Loaded Reconstituted High-Density Lipoprotein Nanoparticle Inhibits Atherosclerotic Plaque Inflammation

  2014cited by this paper
• Darapladib for preventing ischemic events in stable coronary heart disease.

  2014cited by this paper
• Regulation of High-Density Lipoprotein Metabolism

  2014cited by this paper
• Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases.

  2014cited by this paper
• Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.

  2014cited by this paper
• Severe hypertriglyceridemia with pancreatitis: thirteen years' treatment with lomitapide.

  2014cited by this paper
• Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.

  2014cited by this paper
• an update on

  2014cited by this paper
• Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus The AleCardio Randomized Clinical Trial

  2014cited by this paper
• Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.

  2014cited by this paper
• Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease.

  2014cited by this paper
• What is an open label trial?

  2014cited by this paper
• 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

  2014cited by this paper
• Gene silencing approaches for the management of dyslipidaemia.

  2013cited by this paper
• Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile.

  2013cited by this paper
• Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia

  2013cited by this paper
• Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists

  2013cited by this paper
• Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.

  2013cited by this paper
• HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

  2013cited by this paper
• Future of High-Density Lipoprotein Infusion Therapies: Potential for Clinical Management of Vascular Disease

  2013cited by this paper
• Abstract 14196: Evaluation of Isis Apo(a)Rx, an Antisense Inhibitor to Apolipoprotein(a), in Healthy Volunteers

  2013cited by this paper
• Ezetimibe and bile acid sequestrants: impact on lipoprotein metabolism and beyond

  2013cited by this paper
• MicroRNAs and lipoproteins: a connection beyond atherosclerosis?

  2013cited by this paper
• Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist.

  2013cited by this paper
• Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension

  2013cited by this paper
• Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

  2013cited by this paper
• Inhibition of pre-protein convertase serine kexin-9 (PCSK-9) as a treatment for hyperlipidaemia

  2012cited by this paper
• Omega 3 Fatty Acids and Cardiovascular Outcomes: Systematic Review and Meta-Analysis

  2012cited by this paper
• Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins

  2012cited by this paper
• Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

  2012cited by this paper
• Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects.

  2012cited by this paper
• Efficacy and long term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open label trial

  2012cited by this paper
• The PCSK9 decade

  2012cited by this paper
• New lipid‐lowering drugs: an update

  2012cited by this paper
• Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease

  2012cited by this paper
• Diagnosis and treatment of severe hypertriglyceridemia

  2012cited by this paper
• Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.

  2012cited by this paper
• Effects of dalcetrapib in patients with a recent acute coronary syndrome.

  2012cited by this paper
• Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia.

  2011cited by this paper
• A Systematic Review and Meta-analysis

  2011cited by this paper
• Niacin: the only vitamin that reduces cardiovascular events

  2011cited by this paper
• Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.

  2011cited by this paper
• Effects of the New Dual PPARα/δ Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism

  2011cited by this paper
• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

  2011cited by this paper
• Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial.

  2011cited by this paper
• Lipoprotein(a): medical treatment options for an elusive molecule.

  2011cited by this paper
• Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).

  2011cited by this paper
• Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice.

  2011cited by this paper
• Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

  2011cited by this paper
• Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.

  2011cited by this paper
• The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

  2011cited by this paper
• Future challenges for microsomal transport protein inhibitors.

  2010cited by this paper
• Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

  2010cited by this paper
• Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.

  2010cited by this paper
• Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport[S]

  2010cited by this paper
• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

  2010cited by this paper
• Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia.

  2010cited by this paper
• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

  2010cited by this paper
• Safety of anacetrapib in patients with or at high risk for coronary heart disease.

  2010cited by this paper
• Lipid lowering with thyroid hormone and thyromimetics

  2010cited by this paper
• GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects.

  2010cited by this paper
• Lipoprotein(a) as a cardiovascular risk factor: current status

  2010cited by this paper
• Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis

  2010cited by this paper
• Drug Discovery Using Chemical Systems Biology: Identification of the Protein-Ligand Binding Network To Explain the Side Effects of CETP Inhibitors

  2009cited by this paper
• Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors

  2009cited by this paper
• Future challenges for microsomal transport protein inhibitors.

  2009cited by this paper
• Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target

  2009cited by this paper
• Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib and Off-Target Toxicity: A Pooled Analysis of the Rating Atherosclerotic Disease Change by Imaging With a New CETP Inhibitor (RADIANCE) Trials

  2008cited by this paper
• Effects of torcetrapib in patients at high risk for coronary events

  2008cited by this paper
• The World Space Observatory (WSO-UV) - Current status

  2008cited by this paper
• CETP inhibitors to increase HDL cholesterol levels.

  2007cited by this paper
• Safety issues and prospects for future generations of PPAR modulators.

  2007cited by this paper
• Effects of torcetrapib in patients at high risk for coronary events.

  2007cited by this paper
• HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.

  2007cited by this paper
• The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy

  2006cited by this paper
• Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

  2006cited by this paper
• Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of Type 2 diabetes and atherosclerosis

  2006cited by this paper
• Lipid and non-lipid effects of statins.

  2005cited by this paper
• The lipid and non-lipid effects of statins.

  2003cited by this paper
• Randomised, placebo-controlled trial

  2002cited by this paper
• Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation.

  1990cited by this paper
• A RANDOMISED CLINICAL TRIAL

  1989cited by this paper

• Dyslipidaemias and cardiovascular disease: Focus on the role of PCSK9 inhibitors Olga Panagiotopoulou.

  2020cites this paper
• Oxygen role in physiological and molecular markers related to metabolic disorders on in vivo and in vitro models

  2018cites this paper
• Chylomicronemia Syndrome: Very Severe Hypertriglyceridemia and Acute Pancreatitis

  2018cites this paper
• An update on trials of novel lipid-lowering drugs

  2018cites this paper
• Further options for treating lipids in people with diabetes: targeting LDL‐cholesterol and beyond

  2018cites this paper
• Cardiovascular risk reduction: the future of cholesterol lowering drugs.

  2016cites this paper
• Drugs for hypercholesterolaemia - from statins to pro-protein convertase subtilisin kexin 9 (PCSK9) inhibition.

  2016cites this paper
• Camphene, a Plant Derived Monoterpene, Exerts Its Hypolipidemic Action by Affecting SREBP-1 and MTP Expression

  2016cites this paper
• Diabetic Dyslipidemia and Risk of Cardiovascular Disease

  2016cites this paper
• The hinterland of familial hypercholesterolaemia: what do we not know?

  2015cites this paper
• Improving the odds: ezetimibe and cardiovascular disease

  2015cites this paper
• Dyslipidaemia : Current Therapy and Future Prospectus

  2015cites this paper
• Reducing Elevated Plasma LDL Cholesterol: The Central Role of the LDL Receptor

  2014cites this paper
• Dyslipidaemia: what's around the corner?

  2014cites this paper
• Mechanism of action of anti-hypercholesterolemia drugs and their resistance.

  2014cites this paper